162 assets in Mantle Cell Lymphoma

Therapeutic assets addressing Mantle Cell Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Magrolimab Mantle Cell Lymphoma	National Cancer Institute (NCI)	P1	D (30)
ms-553 Mantle Cell Lymphoma	MingSight Pharmaceuticals, Inc	P1/2	D (30)
Mtm-H-001 Mantle Cell Lymphoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	N/A	D (30)
Pomalidomide Mantle Cell Lymphoma	The First Affiliated Hospital of Soochow University	N/A	D (30)
Apg-3288 Mantle Cell Lymphoma	Ascentage Pharma Group Inc.	P1	NR ()
Icp-248 Mantle Cell Lymphoma	Beijing InnoCare Pharma Tech Co., Ltd.	P2	NR ()

Showing 151 to 162 of 162 assets

PreviousPage 4 of 4Next